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Introduction
Breast cancer is the most common malignancy among women 
worldwide [1]. Due to increased screening, the majority of 
patients present with early- stage disease [2]. Treatment of 
choice in early breast cancer (stages 0, 1, and 2) is surgical 
resection followed by adjuvant chemotherapy according to 
clinicopathological risk factors [3, 4]. The known prognostic 
factors are axillary nodal status, tumor size, tumor 
pathology, tumor grade, peritumoral lymphatic vessel and 
vascular invasion, hormonal receptors, proliferation markers, 
ethnicity, and age, among others [5]. In addition, five intrinsic 
subtypes based on gene expression profiles have shown 
distinct tumor phenotypes in predicting patient outcomes 
[6, 7]. Genomic risk stratification has been also useful in 
selecting patients who would benefit from adjuvant chemo-
therapy [8]. Due to limitations preventing the routine use 
of gene expression profiling, immunohistochemistry (IHC) 
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Abstract
This study was to investigate a hierarchical prognostic model using clinico-
pathological factors and 18F- fludeoxyglucose (FDG) uptake on positron emission 
tomography/computed tomography (PET/CT) for recurrence- free survival (RFS) 
in patients with early breast cancer who underwent surgery without neoadjuvant 
chemotherapy. A total of 524 patients with early breast cancer were included. 
The Cox proportional hazards model was used with clinicopathological variables 
and maximum standardized uptake value (SUVmax) on PET/CT. After classi-
fication and regression tree (CART) modeling, RFS curves were estimated using 
the Kaplan–Meier method and differences in each risk layer were assessed using 
the log- rank test. During a median follow- up of 46.2 months, 31 (5.9%) patients 
experienced recurrence. The CART model identified four risk layers: group 1 
(SUVmax ≤6.75 and tumor size ≤2.0 cm); group 2 (SUVmax ≤6.75 and Luminal 
A [LumA] or TN tumor >2.0 cm); group 3 (SUVmax ≤6.75 and Luminal B 
[LumB] or human epidermal growth factor receptor 2 [HER2]- enriched] tumor 
>2.0 cm); group 4 (SUVmax >6.75). Five- year RFS was as follows: 95.9% (group 
1), 98% (group 2), 82.8% (group 3), and 85.4% (group 4). Group 3 or group 
4 showed worse prognosis than group 1 or group 2 (group 1 vs. group 3: 
P = 0.040; group 1 vs. group 4: P < 0.001; group 2 vs. group 3: P = 0.016; 
group 2 vs. group 4: P < 0.001). High SUVmax (>6.75) in primary breast 
cancer was an independent factor for poor RFS. In patients with low SUVmax, 
LumB or HER2- enriched tumor >2 cm was also prognostic for poor RFS, similar 
to high SUVmax. 
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staining for hormonal receptors and human epidermal growth 
factor receptor 2 (HER2) has been preferred as a therapy- 
oriented surrogate of intrinsic subtype [9, 10].
18F- fludeoxyglucose (FDG) positron emission tomogra-
phy/computed tomography (PET/CT) has advantages over 
conventional imaging modalities in that it offers noninvasive, 
semiquantitative information about metabolically active 
tumor burden, tumor biology, and patient prognosis [11–13]. 
Unlike pathological and genomic prognostic factors, clini-
cally relevant information can be provided in preoperative 
settings with potential therapeutic implications. Although 
maximum standardized uptake value (SUVmax) in primary 
breast cancer has been found to be an independent prog-
nostic factor for survival, studies have included patient 
populations with different risks for recurrence by including 
both early and locally advanced cancers, with or without 
neoadjuvant chemotherapy. Nevertheless, a risk stratification 
model using metabolic variables on PET/CT combined with 
other known prognostic factors has not been proposed.
The purpose of this study was to investigate the prog-
nostic value of 18F- FDG uptake in the primary tumor for 
recurrence- free survival (RFS) in patients with early breast 
cancer who underwent surgery without neoadjuvant chemo-
therapy. In addition to conventional statistical modeling of 
prognosis, a hierarchical prognostic system was applied to 
identify further synergistic/antagonistic interactions between 
clinicopathological prognostic factors and 18F- FDG uptake.
Materials and Methods
Patients
Data from patients with breast cancer who underwent 18F- 
FDG PET/CT at initial staging between January 2008 and 
December 2013 were retrieved from the institutional medical 
database. Patients were included if they had pathologically 
proven breast cancer and IHC results for estrogen receptor 
(ER), progesterone receptor (PR), HER2, and Ki- 67 status. 
To be included, patients also had to have undergone mas-
tectomy with sentinel lymph node dissection and/or axillary 
lymph node dissection without neoadjuvant treatment. 
Among these, patients with locally advanced breast cancer 
(N2/3 classified according to 7th edition of American Joint 
Committee on Cancer [AJCC])[14] were excluded. Tumors 
<1 cm in size were excluded to minimize a partial- volume 
averaging effect affecting semiquantitative measurement of 
18F- FDG uptake. Patients who had bilateral breast cancers 
were excluded. Patients visited the hospital every 3 months 
for the first year of follow- up. Routine examinations, 
including breast sonography, mammography, and whole 
body bone scan, were performed every 6 months for the 
first year and annually thereafter. Whenever abnormal 
findings were noted, further diagnostic studies were 
performed for confirmation. Patients without regular follow-
 up data were excluded. Finally, 524 patients were included 
in the analysis (Fig. 1). This study was approved by the 
Institutional Review Board of our Hospital. Given the 
retrospective nature of this study and the use of anonymized 
data, the requirement for informed consent was waived.
PET/CT imaging
PET/CT was performed using a scanner (Discovery STE; 
GE Healthcare, Milwaukee, WI or Biograph TruePoint 40; 
Siemens Medical Systems, Knoxville, TN) with 16- or 40- 
slice CT, respectively. Patients fasted for at least 6 h before 
imaging, and glucose levels in the peripheral blood were 
≤140 mg/dL before the injection of 18F- FDG. An 18F- FDG 
dose of approximately 5.5 MBq/kg was administered intra-
venously 1 h before image acquisition. After the initial 
low- dose CT study (Discovery STE, 30 mA, 130 kVp or 
Biograph TruePoint 40, 36 mA, 120 kVp), a standard PET 
protocol was used to scan from the neck to the proximal 
thighs with an acquisition time of 2.5 min per bed posi-
tion in the three- dimensional mode. PET images were 
reconstructed using ordered subset expectation maximiza-
tion with CT images for attenuation correction.
Measurement of PET parameters
Two experienced nuclear medicine physicians reviewed 
all PET/CT images; discrepancies were resolved by 
Figure 1. Flow diagram of patients included in the current study. FDG 
PET/CT indicates 18F- fludeoxyglucose positron emission tomography/
computed tomography; IHC immunohistochemistry.
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consensus. Metabolic parameters were measured using 
Volume Viewer software (GE Healthcare, USA). For semi-
quantitative analysis, a volume of interest was drawn for 
each lesion to measure SUVmax. SUVmax was calculated 
using the following formula: (decay- corrected activity 
[kBq]/tissue volume [mL])/(injected 18F- FDG activity 
[kBq]/body mass [g]).
Histologic evaluation and categorization of 
molecular subtypes
All patients underwent surgical resection for breast cancer 
with sentinel lymph node biopsy and/or axillary lymph 
node dissection. Histologic type, tumor size, tumor grade, 
and lymphovascular invasion (LVI) status were determined 
from the surgically excised specimens. Tumor, node, and 
metastasis (TNM) staging was performed according to 
the 7th edition of the AJCC [14]. The histologic grade 
of each tumor was determined using the modified Bloom–
Richardson classification [15]. Formalin- fixed, paraffin- 
embedded tissue blocks were used for IHC; the expression 
status of ER, PR, HER2, and Ki- 67 was determined by 
IHC staining of the surgical specimen. Primary antibodies 
against ER (Clone SP1; Neomarkers for Lab Vision, 
Fremont, USA), PR (Clone PgR 636; DAKO, Glostrup, 
Denmark), HER2 (Clone Polyclonal; DAKO, Glostrup, 
Denmark), Ki67 (Clone MIB- 1; DAKO, Glostrup, 
Denmark) were used. ER positivity (+) and PR (+) were 
defined as the presence of ≥1% positively stained nuclei 
in 10 high- power fields. HER2 staining was analyzed 
according to the American Society of Clinical Oncology/
College of American Pathologists guidelines[16]. The inten-
sity of HER2 staining was scored as 0, 1+, 2+, or 3+. 
Tumors with a 3+ score were considered to be HER2 
(+), whereas those with a 0 or 1+ score were considered 
to be HER2 negative (−). Tumors with a 2+ score were 
subjected to fluorescence in situ hybridization analysis to 
determine HER2 status. For Ki- 67, nuclear staining ≥14% 
was considered to be high- level expression. According to 
different combinations of ER, PR, HER2, and Ki- 67, the 
patients were categorized into four different molecular 
subtypes as follows: Luminal A (LumA): ER (+) and/or 
PR (+), HER2 (−), and Ki- 67 low (<14%); Luminal B 
(LumB): ER (+) and/or PR (+), HER2 (−), and Ki- 67 
high (≥14%) or ER (+) and/or PR (+), HER2 (+), and 
any Ki- 67 index; HER2- enriched: ER (−), PR (−), but 
HER2 (+); and triple negative (TN): ER (−), PR (−), 
and HER2 (−).
Statistical analysis
RFS was defined as the time from the operation date to 
the date of cancer recurrence. The prognostic values of 
clinicopathological factors, including age, tumor size, nodal 
status, TNM stage, histologic type, histologic grade, LVI, 
molecular subtypes, proliferation index, treatment modali-
ties, and SUVmax, were assessed using a Cox proportional 
hazards model for RFS. Hazard ratio (HR) with Wald 
95% confidence intervals (CI) was provided for the model. 
All continuous variables were grouped into two categories 
according to the optimal cutoff values determined using 
receiver operating characteristic (ROC) curve analysis. 
Multicollinearity among independent variables was evalu-
ated using Spearman rank correlation coefficient before 
multivariate analysis.
Next, to identify further synergistic/antagonistic interac-
tions between prognostic factors, a classification and regres-
sion tree (CART) was generated for RFS. Left- truncated 
and right- censored (LTRC) CART is a prognostic system 
with a hierarchical structure based on recursive partition-
ing that builds a decision tree to find subgroups at higher 
risk for recurrence. Factors that were statistically significant 
in univariate analyses were included in the CART analysis. 
Each node on the decision trees included subgroups of 
a population with common characteristics influencing RFS. 
HRs of each group elicited by CART model were assessed 
using Cox proportional hazard model. Finally, cumulative 
RFS curves of each risk layer were estimated using the 
Kaplan–Meier method, and the statistical differences among 
the risk layers were compared using the log- rank test 
with pairwise comparison to account for multiple com-
parison correction.
All statistical analyses were performed using SPSS ver-
sion 23 (IBM Corporation, Armonk, NY, USA) for 
Windows (Microsoft Corporation, Redmond, WA, USA) 
and R 3.33.0 software (The R Foundation for Statistical 
Computing, Vienna, Austria) with necessary analytical 
packages such as LTRC trees, rpart, and survival; P < 0.05 
was considered to be statistically significant.
Results
Patient characteristics
The clinicopathological characteristics of the 524 female 
patients (median age 50 years [range, 27–82 years]) are 
summarized in Table 1. There were 270 of 524 (51.5%) 
patients with TNM stage I and 254 of 524 (48.5%) with 
stage II cancer. Of the 125 of 524 (23.9%) patients with 
lymph node metastasis (N1), 23 of 524 (4.4%) had known 
N1 metastasis according to ultrasonography- guided biopsy 
before surgery, and 102 of 524 (19.5%) exhibited lymph 
node metastasis only by sentinel lymph node sampling. 
There were 225 of 524 (42.9%) patients with LumA, 155 
of 524 (29.6%) with LumB, 42 of 524 (8.0%) with HER2- 
enriched, and 102 of 524 (19.5%) with TN subtypes. The 
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mean SUVmax of the primary tumors was 5.51 ± 4.10. 
Representative PET/CT images of patients in each molecular 
subtype are shown in Figure 2.
During a median follow- up duration of 46.2 months 
(range, 5.4–95.2 months), 31 of 524 (5.9%) patients expe-
rienced recurrence (8 locoregional recurrences, 23 distant 
metastases). Fourteen of the 270 patients with stage I and 
17 of the 254 patients with stage II cancer had recurrence. 
According to molecular subtype, there was recurrence in 
8 of 225 (3.6%) with LumA, 10 of 155 (6.5%) with LumB, 
4 of 42 (9.5%) with HER2- enriched, and 9 of 102 (8.8%) 
with TN.
Clinicopathological and imaging prognostic 
factors for RFS
Optimal cutoff values for SUVmax and size were >6.75 
and >2 cm, respectively. In univariate analysis, SUVmax 
(>6.75), size (>2.0 cm), and TN subtype were significant 
prognostic factors for RFS. In multivariate analysis, 
SUVmax was the only independent prognostic factor for 
RFS (HR 2.6 [CI, 1.1–6.1]; P = 0.028) (Table 2).
Risk stratification using CART analysis
CART modeling was performed using statistically significant 
variables found in the univariate analysis to identify sub-
groups at higher risk for recurrence. Accordingly, SUVmax 
>6.75, tumor size >2.0 cm, and molecular subtypes were 
Table 1. Patient characteristics.
Variable
Age, median year [range] 50 (27–82)
SUVmax (g/mL) 5.51 ± 4.10




Sentinel LN positive 102 (19.5%)
Axillary LN positive 23 (4.4%)
TNM stage (n)
I/II 270 (51.5%)/254 (48.5%)
Histologic type (n)
IDC/ILC/Other1 457 (87.2%)/16 (3.1%)/51 
(9.7%)
Histologic grade (n)
1/2/3 110 (21.0%)/240 
(45.8%)/174 (33.2%)
Lymphovascular invasion (n)
Negative/Positive 465 (88.7%)/59 (11.3%)
Ki67 (%) 21.78 ± 21.70
Molecular subtype (n)
LumA/LumB/HER2- enriched/TN 225 (42.9%)/155 (29.6%)/42 
(8.0%)/102 (19.5%)
Adjuvant chemotherapy (n)
Done/Not done 430 (82.1%)/94 (17.9%)
LumA, Luminal A; LumB, Luminal B; HER2, human epidermal growth 
factor receptor 2; TN, triple negative.
Data are reported as mean with standard deviation unless otherwise 
specified.
1Other: primary breast cancer other than invasive ductal carcinoma 
(IDC) or invasive lobular carcinoma (ILC).
Figure 2. Representative 18F- fludeoxyglucose positron emission tomography/computed tomography images of patients in each molecular subtype. 
(A) Luminal A subtype (SUVmax = 3.30, tumor size = 1.8 cm); (B) Luminal B subtype (SUVmax = 5.86, tumor size = 2.0 cm); (C) human epidermal 
growth factor receptor 2- enriched subtype (SUVmax = 6.80, tumor size = 1.9 cm); (D) triple negative subtype (SUVmax = 9.50, tumor size = 1.8 cm). 
SUVmax indicates maximum standardized uptake value.
A B
C D
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included in CART analysis. The resulting CART model 
revealed four risk layers based on SUVmax, tumor size, 
and molecular subtype: group 1 (SUVmax ≤6.75 and tumor 
size ≤2.0 cm); group 2 (SUVmax ≤6.75, tumor size >2.0 cm, 
and LumA or TN); group 3 (SUVmax ≤6.75, tumor size 
>2.0 cm, and LumB or HER2- enriched); group 4 (SUVmax 
>6.75) (Fig. 3). There were 278 (53%) patients in group 
1, 52 (10%) in group 2, 33 (6%) in group 3, and 161 
(31%) in group 4. LumA was the most common subtype 
in group 1, and TN was the most common in group 4.
Kaplan–Meier survival analysis in four risk 
layers on CART modeling
According to the risk layers, the 5- year RFS was 95.9% 
in group 1, 98% in group 2, 82.8% in group 3, and 
85.4% in group 4 (Fig. 3). Group 3 or group 4 demon-
strates worse prognosis than group 1 or group 2 (group 
1 vs. group 3: P = 0.040 after adjustment; group 1 vs. 
group 4: P < 0.001 after adjustment; group 2 vs. group 
3: P = 0.016 after adjustment; group 2 vs. group 4: 
P < 0.001 after adjustment). No significant difference in 
RFS was observed between patients in group 1 and those 
in group 2 (P = 0.553 after adjustment). The patients in 
group 3 showed no remarkable difference in RFS 
compared with those in group 4 (P = 0.847 after 
adjustment).
Discussion
Because the majority of patients with breast cancer present 
at an early stage of disease, we included only a large 
population of stage I and II breast cancer patients who 
underwent upfront surgery without neoadjuvant chemo-
therapy [2, 3]. High SUVmax (> 6.75) in the primary 
tumor was the only independent prognostic factor for 
RFS in multivariate analysis. Other than SUVmax, tumor 
size and molecular subtype were significant in univariate 
analysis. In general, nodal status seems to be the most 
powerful prognostic factor for RFS in early- stage breast 
cancer [17, 18]. Regardless, it was not prognostic for RFS 
in this study. There were 125 of 524 (23.9%) patients 
with N1 metastasis, in which only a small number 
(n = 23/524 [4.4%]) had N1 metastasis confirmed before 
surgery. The remaining 102 of 524 (19.5%) patients had 
N1 disease according to sentinel lymph node sampling. 
Most N1 metastasis was not clinically detectable, and 
improved surgical removal of metastatic lymph nodes and 
effective adjuvant therapy may have contributed to the 
result.
Table 2. Univariate and Multivariate Analysis of Recurrence- free Survival.
Variable
Univariate analysis Multivariate analysis
P- value Hazard ratio (95% CI) P- value Hazard ratio (95% CI)
Age (≤35 vs. >35 years) 0.699 0.75 (0.17–3.16)
SUVmax (≤6.75 vs. >6.75) 0.001 3.50 (1.69–7.23) 0.028 2.60 (1.10–6.14)
Tumor size (≤2 cm vs. 
>2 cm)
0.019 2.33 (1.15–4.74) 0.205 1.63 (0.76–3.46)
Nodal status (Negative vs. 
Positive)
0.750 0.74 (0.30–1.82)




Other1 0.52 1.40 (0.49–4.02)
Histologic grade (1 or 2 vs. 
3)
0.327 1.42 (0.70–2.91)
LVI (Negative vs. Positive) 0.830 1.13 (0.39–3.24)
Ki67 (≤14% vs. >14%) 0.054 2.09 (0.98–4.45)
Molecular subtype 
LumA 1.00 1.00
LumB 0.183 1.18 (0.74–4.76) 0.658 1.24 (0.46–3.33)
HER2- enriched 0.108 2.67 (0.80–8.91) 0.529 1.51 (0.41–5.49)
TN 0.046 2.63 (1.01–6.83) 0.579 1.35 (0.46–3.91)
Adjuvant chemotherapy 
(Done vs. Not done)
0.483 1.45 (0.50–4.16)
CI, Confidence interval; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; LumA, Luminal A; LumB, 
Luminal B; HER2, human epidermal growth factor receptor 2; TN, triple negative; vs. , versus.
1Other: primary breast cancer other than IDC or ILC.
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SUVmax at staging has been prognostic for RFS in 
patients with operable breast cancer [19–25]. However, 
no studies have evaluated the interactions between clin-
icopathological and metabolic prognostic factors for risk 
stratification. We used CART analysis to evaluate high- 
order associations among the significant factors in uni-
variate analysis for further risk stratification. SUVmax 
>6.75, tumor size >2.0 cm, and molecular subtypes were 
included in the analysis, resulting in four different risk 
layers. Among the four risk groups based on CART mod-
eling, patients in groups 3 and 4 showed no significant 
difference in 5- year RFS rates (82.8% and 85.4%, respec-
tively). Patients in groups 1 and 2 also showed no 
difference in 5- year RFS rates (95.9% and 98%, respec-
tively). The 5- year RFS rates in group 3 or group 4 were 
significantly worse than those in group 1 or group 2.
As expected in multivariate analysis, high SUVmax was 
the highest- order risk factor for RFS on CART modeling. 
In group 4 (SUVmax >6.75), neither size nor molecular 
subtype was significant for further risk classification. This 
group demonstrated a higher HR (7.29) for RFS. In the 
remaining patients (groups 1, 2, and 3) with low SUVmax 
(≤6.75), tumor size was the next classification factor. Patients 
with a tumor size ≤2 cm represented a separate risk layer 
with a lower HR (1.36) for RFS (group 1). In patients 
with tumor size >2 cm, there were two different risk 
Figure 3. Classification and regression tree analyses to identify synergistic/antagonistic associations between prognostic factors. Square boxes 
indicate, respectively, intermediate and terminal subsets of patients defined by the sequential splitting process. There are four terminal risk groups. 
The numbers after molecular subtype are the number of recurrences of the total number of patient in each subtype. Cox proportional hazard model 
calculated HRs of each group. * = statistically significant difference for pairwise comparison using log- rank test. HER2 = human epidermal growth 
factor receptor 2; LumA = Luminal A; LumB = Luminal B; TN = triple negative.
1133© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
18F- FDG Uptake in Early Breast CancerJ. Cha et al.
layers according to molecular subtype. In patients with 
LumA or TN subtypes (group 2), the HR (1.00) was similar 
to that of group 1, whereas it was 8.67 in patients with 
LumB or HER2- enriched subtypes (group 3), similar to 
that of group 4. Similar to high SUVmax, LumB or HER2- 
enriched breast cancers >2 cm appeared to be important 
in predicting worse RFS in patients with low SUVmax.
TN breast cancer is known to demonstrate the worst 
survival, whereas LumA has the best survival [26]. However, 
there were interesting risk stratification patterns in patients 
with TN or LumA subtype in this study. Despite the 
known poor prognosis of the TN subtype, of the 102 
patients with TN, 39 (38%) with low SUVmax showed 
significantly better RFS than the remaining 63 (62%) 
patients with high SUVmax. In contrast to LumB or 
HER2- enriched, tumor size was not prognostic in TN 
when SUVmax was low. Given that TN subtype demon-
strates heterogeneous histology as well as gene expressions 
[27], SUVmax appeared to have potential in differentiating 
patients with different risks for RFS in TN subtype.
In the LumA subtype, there is a high clinical demand 
for techniques to identify patients who could benefit from 
toxic adjuvant chemotherapy. Oncotype DX assay 
(Genomic Health), based on the expression of 21 genes, 
has been useful in scoring the likelihood of distant metas-
tasis and aiding in treatment decisions [28]. In this study, 
only 23 (10.2%) of the 225 patients with LumA demon-
strated high SUVmax and worse RFS. The remaining 202 
(89.8%) patients demonstrated low SUV max and better 
RFS. Similar to the TN subtype, tumor size was not 
prognostic in LumA when SUVmax was low. Further 
studies are needed to determine the value of SUVmax to 
predict RFS and to select patients for adjuvant chemo-
therapy in LumA breast cancer.
The present study had several limitations, the first of 
which was its retrospective design. However, we analyzed 
a large homogenous population of patients with stage I 
and stage II breast cancer with complete pathological 
results. Second, we excluded patients whose primary tumor 
diameter was <1 cm to avoid a partial- volume averaging 
effect on SUVmax measurement, which may have resulted 
in exaggerated prognostic value of SUVmax on small size 
tumors [29, 30]. Even with partial- volume correction, 
overcorrection can be problematic in tumors with diam-
eters <1.5 times the full- width at half- maximum [31]. 
Regardless, performing 18F- FDG PET/CT in patients with 
breast cancer tumors <1 cm is less likely.
Conclusion
In this study, we proposed a risk stratification model 
using clinicopathological and metabolic prognostic factors 
in stage I and II breast cancer patients who underwent 
surgery without neoadjuvant chemotherapy. High SUVmax 
(>6.75) in the primary tumor was an independent prog-
nostic factor for poor RFS. In patients with low SUVmax, 
LumB or HER2- enriched tumor >2 cm was a poor prog-
nostic factor for RFS, similar to high SUVmax.
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